Actuate Therapeutics (NASDAQ:ACTU) Trading 0.8% Higher – Here’s What Happened

Actuate Therapeutics (NASDAQ:ACTU)’s share price traded up 0.8% during trading on Monday . The stock traded as high as $9.08 and last traded at $8.69. 73,427 shares traded hands during trading, an increase of 55% from the average session volume of 47,485 shares. The stock had previously closed at $8.62.

Actuate Therapeutics Price Performance

The firm’s 50-day simple moving average is $8.38.

Actuate Therapeutics (NASDAQ:ACTU) last released its quarterly earnings data on Tuesday, September 24th. The company reported ($4.20) EPS for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Actuate Therapeutics stock. KG&L Capital Management LLC bought a new position in Actuate Therapeutics (NASDAQ:ACTU) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 12,000 shares of the company’s stock, valued at approximately $89,000. KG&L Capital Management LLC owned about 0.06% of Actuate Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

About Actuate Therapeutics

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.